UnitedHealth (UNH) vs Healthcare Sector (XLV)

UNH at 6.10 percent of XLV is the fourth-largest position. The XLV top five hierarchy: Eli Lilly 13.80 percent (GLP-1 obesity drug franchise), Johnson and Johnson 10.55 percent (diversified pharma + medtech), AbbVie 6.74 percent (post-Humira immunology), UnitedHealth 6.10 percent (managed care leader), Merck 5.40 percent (Keytruda oncology).

The UNH/XLV ratio currently trades at approximately 2.37 (UNH $350.82 / XLV $147.77). The ratio peaked near 3.50 in late 2023 (before the 2024 DOJ investigation overhang) and bottomed near 2.05 during the worst of the 2024-2025 drawdown. The current 2.37 reflects partial recovery as Q1 2026 results stabilized and management raised guidance.

UNH lost roughly 30 percent peak-to-trough during 2024-2025 from its October 2023 peak near $530. Three drivers compounded.

First, Medicare Advantage margin compression: 2024 MA reimbursement updates were less generous than expected, and rising medical-cost trends (post-COVID delayed care surge) pressured insurer margins across the industry. UnitedHealthcare margins compressed from approximately 6 percent in 2023 to approximately 5 percent in 2024.

Second, the Change Healthcare cyber incident: February 2024 ransomware attack on UNH-owned Change Healthcare disrupted claims processing across the US healthcare system. The incident produced approximately $2 billion in remediation costs plus reputation damage and Senate hearings.

Third, the DOJ investigation: announced 2024 into UnitedHealthcare's Medicare Advantage billing practices, focusing on diagnoses that increased federal payments. Allegations include inflated risk scores and diagnoses added without physician confirmation, raising potential fraud questions. The Senate Permanent Subcommittee on Investigations also accused UnitedHealth of "aggressively gaming" Medicare Advantage to inflate reimbursement.

The combined drag pulled XLV by approximately 2 percentage points given UNH's 6.10 percent weight.

UNH year-to-date 2026 is approximately +5 percent versus XLV approximately flat. The recovery reflects three factors. First, management raised 2026 EPS guidance to at least $18.25, indicating margin recovery from 2024-2025 trough. Second, Q1 2026 results showed Medicare Advantage cost trends moderating from the 2024-2025 peak, suggesting the worst of the margin compression has passed.

Third, the DOJ investigation has moved from initial-reporting phase to lengthy procedural phase without immediate adverse rulings. The market has partially priced in the worst-case scenario (significant fines, divestiture demands) and is now in wait-and-watch mode. Morgan Stanley's Top Pick designation and $375 price target reflect the stabilization view.

The 2026 Medicare Advantage updates have been mixed. UnitedHealthcare scaled back MA offerings in 13 states, affecting 180,000 seniors with plan changes for 2026. The strategic rationalization improves margins but reduces revenue growth. UNH expects 2026 MA enrollment growth to be modestly positive at low single digits versus 8-10 percent historically.

UnitedHealth is structurally different from any other XLV holding. The company has two major business segments. UnitedHealthcare (the insurance business) generates approximately 55 percent of revenue and serves 50+ million members across commercial, Medicare Advantage, Medicaid, and supplemental products. Optum (the healthcare services and pharmacy benefit manager) generates 45 percent of revenue with three sub-segments: OptumHealth (care delivery), OptumInsight (data and analytics), and OptumRx (PBM).

The combined model means UNH performance reflects health-insurance economics (premium growth versus medical-cost trend), pharmacy economics (PBM rebate and spread economics), and care delivery economics. The diversification provides multiple offsetting margin levers. When insurance margins compress, Optum margin growth can offset; when Optum faces pricing pressure, insurance can grow.

No other XLV constituent has the integrated insurance-plus-services model. Pure-play insurers (Humana, Cigna) have similar insurance economics but no Optum-equivalent services arm. Pure-play health-services names (CVS, Walgreens) have services but no UnitedHealthcare-scale insurance.

XLV is dominated by pharma and biotech (Lilly, J&J, AbbVie, Merck combined approximately 36.5 percent). UNH is the only managed-care representative in the XLV top 10. The structural difference produces specific divergences.

During drug-pricing political cycles (2017 Trump tweets, 2022 IRA negotiations, 2024-2025 enforcement), pharma names face pressure while UNH benefits from PBM pricing dynamics. During managed-care political cycles (2024 DOJ investigations, Senate hearings), UNH faces pressure while pharma names benefit. During GLP-1 boom episodes (2023 Lilly stock doubling), Lilly drives XLV outperformance with UNH unaffected.

The UNH/XLV ratio captures the rotation between these two healthcare sub-narratives. The 2024-2025 drawdown coincided with simultaneous UNH-specific issues (Change cyber, DOJ) and Lilly-driven XLV strength (GLP-1 franchise). The 2026 recovery reflects UNH-specific stabilization while Lilly faces increased GLP-1 competition (Novo, Pfizer, Roche pipeline).

Medicare Advantage is the central UNH-vs-XLV theme. MA enrollment has grown from approximately 25 percent of Medicare-eligible seniors in 2010 to 53 percent in 2024, totaling approximately 33 million enrollees. UnitedHealthcare is the largest MA insurer with approximately 28 percent market share (~9.3 million enrollees).

MA economics depend on three factors. First, CMS reimbursement (driven by federal benchmarks). Second, medical-cost trend (driven by hospital and physician utilization rates). Third, risk-adjustment mechanics (diagnoses captured during plan year drive future-year payments, the central DOJ investigation focus).

The 2024-2025 MA stress reflected reimbursement updates falling behind medical-cost trends. The 2026 setup has stabilizing reimbursement and moderating cost trends. The DOJ investigation, if it produces material findings, could disrupt the risk-adjustment economics that have been a structural UNH advantage. If it produces no material findings, UNH likely outperforms XLV by 10-15 percent over 12 months as the overhang clears.

Three regimes describe UNH-vs-XLV. Regime 1 (2010-2019 healthcare expansion): MA enrollment growth + Optum scaling drove UNH to consistent 5-10 percent annual outperformance vs XLV. Regime 2 (2020-2023 healthcare consolidation): UNH stabilized as XLV pharma names benefited from COVID vaccine and obesity-drug developments; UNH-vs-XLV roughly flat. Regime 3 (2024-2025 UNH idiosyncratic stress): UNH underperformed XLV by 25 percentage points cumulatively on Change cyber, DOJ investigation, and MA margin compression. Regime 4 (current 2026 stabilization): UNH partially recovering, outperforming XLV by approximately 5 percentage points YTD.

The long-run pattern: UNH outperforms XLV during normal expansion periods because of its structural growth lever (MA enrollment expansion). UNH underperforms during idiosyncratic stress periods (cyber incidents, regulatory investigations, margin compression episodes). The 2026 question is whether UNH returns to its long-run outperformance pattern or whether the structural MA growth thesis has been compromised.

UNH at $350.82 trades at approximately 19x forward earnings (using $18.25 2026 EPS guidance) and approximately 17x 2027 consensus earnings of approximately $20.50. The XLV-weighted average forward P/E is approximately 18-19x. UNH is therefore trading roughly in line with the broader XLV multiple.

The in-line multiple reflects the market's view that UNH has resolved most of its idiosyncratic stress but residual DOJ overhang prevents premium re-rating. Pre-2024 UNH typically traded at 22-25x forward earnings, a 4-6 turn premium to XLV reflecting its growth and quality. Closing that premium gap (returning to 22-23x) would require successful DOJ resolution and demonstrated MA margin recovery through 2026.

Morgan Stanley's $375 price target implies approximately 7 percent upside from current levels and assumes partial premium-multiple recovery to approximately 20.5x forward earnings.

For pair traders, the UNH/XLV ratio currently trades at 2.37. The 12-month range is 2.05 to 2.50. The 5-year range is 2.05 to 3.50 (October 2023 peak). Above 2.55 indicates UNH extended outperformance (potentially mean-reversion territory in current overhang environment); below 2.10 indicates renewed UNH stress.

Long UNH / short XLV captures the UNH-recovery bet: benefits from DOJ resolution, MA margin recovery, and Lilly facing GLP-1 competition. Short UNH / long XLV benefits from new UNH-specific stress (DOJ adverse ruling, additional cyber incident, MA margin re-compression) or Lilly GLP-1 dominance reasserting. Position sizing should account for UNH 25 percent annualized volatility versus XLV 15-17 percent.

The pair has produced significant cumulative returns over 2023-2026 cycle: long UNH short XLV would have lost approximately 30 percent through 2024-2025 then gained approximately 10 percent in 2026 partial recovery. The net outcome is highly path-dependent on DOJ investigation timeline and MA margin trajectory.

UNH at $350.82, XLV at $147.77, ratio at 2.37. UNH 2026 EPS guidance >=$18.25. Morgan Stanley Top Pick at $375. Year-to-date UNH +5 percent vs XLV approximately flat. Q1 2026 results stabilized; DOJ investigation in procedural phase without immediate adverse rulings.

Forward-looking: UNH Q2 2026 earnings (mid-July typical) will provide updated MA cost-trend data. The 2026 Medicare Advantage open enrollment period (October-December) will determine 2027 enrollment trajectory. The DOJ investigation timeline is uncertain; resolution within 12-18 months is possible. Lilly Q1 2026 earnings on April 30 will indicate GLP-1 franchise momentum that affects Lilly weight in XLV.

Watch the UNH/XLV ratio for any move outside 2.20 to 2.55 range. Above 2.60 indicates DOJ overhang clearing (premium-multiple recovery underway); below 2.10 indicates renewed UNH stress (likely DOJ adverse development or MA cost trend re-acceleration).